Table 1.
The NSCLC patients information and numbers of T cells sequenced
| Patient ID | Clinical Information | Molecular Information | Number of Collected Cells | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Response | Cancer Type | Age | Sex | Stage | Time Points | PD-L1 (%) | Neoantigens | CD8+ T cells | CD4+ T cells | Summary | |
| Pt 1 | Y | lung adenocarcinoma | 54 | M | IV | Pre/On/Pro | 20 | ERBB4R1250Q, KRASG12D | − /477/137 | − /418/120 | 1152 |
| Pt 2 | Y | lung adenocarcinoma | 51 | F | IV | Pre/On/Pro | 5 | NFE2L2G31A, KRASG12V | 68/151/168 | 76/130/147 | 740 |
| Pt 3 | Y | lung squamous cell carcinoma | 59 | M | IV | Pre/On/Pro | 40 | TP53R158L | 48/317/244 | 50/201/255 | 1115 |
| Pt 4 | N | lung adenocarcinoma | 75 | F | IV | Pre | 0 | Not detected | 51 | 52 | 103 |
Pre/On/Pro represent the time points pre-treatment, on-treatment and progression